Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cord Blood Stem Cell Transplantation Study (COBLT)

This study has been completed.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: October 27, 1999
Last updated: April 12, 2016
Last verified: January 2008
To evaluate if HLA-mismatched, unrelated-donor umbilical cord blood stem and progenitor cell units (UCBU) offered a clinically acceptable alternative to matched unrelated-donor allogeneic bone marrow for transplantation with 180-day disease free survival as the endpoint. HLA typing was performed using DNA-base high resolution methods to determine HLA alleles. Patients with "true" HLA 3/6 and 4/6 matches were evaluated. In addition, a separate study in adults addressed the problem of limited cell dose and engraftment failure. The study was not planned as a randomized comparative clinical trial. Instead, it is a phase II/III efficacy study.

Condition Intervention Phase
Anemia, Aplastic
Fanconi Anemia
Hematologic Diseases
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Procedure: stem cell transplantation
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1996
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   up to 55 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Mothers of Infant-donors must complete a medical history form, have an uncomplicated delivery, and deliver at UCLA or Duke.

Patients are those who need a transplant but don't have a matched marrow donor or can't wait to find one.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000603

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
OverallOfficial: Shelly Carter The EMMES Corporation
OverallOfficial: Joanne Kurtzberg Duke University
  More Information

Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00000603     History of Changes
Other Study ID Numbers: 316 
Study First Received: October 27, 1999
Last Updated: April 12, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Immunologic Deficiency Syndromes
Hematologic Diseases
Fanconi Anemia
Fanconi Syndrome
Anemia, Aplastic
Severe Combined Immunodeficiency
Bone Marrow Diseases
Precancerous Conditions
Immune System Diseases
Anemia, Hypoplastic, Congenital
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Metabolism, Inborn Errors
Infant, Newborn, Diseases processed this record on October 25, 2016